News
Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data presented at the American Thoracic Society International Conference.Quality ...
Discover a study that highlights dupilumab’s consistent efficacy in eosinophilic oesophagitis, even among patients with ...
[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...
Dupilumab may be a promising therapy for JAK inhibitor-resistant severe AA patients, especially pediatric patients. Case presentation. We report hair regrowth over all of the scalp, eyebrows, and ...
Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...
A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...
However, Dupilumab led to improvement in abdominal pain and iron deficiency anemia with endoscopic and histologic improvements (Table 3 and Table 4). The second patient with further jejunal ...
Number 5: Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory ...
The main evidence for dupilumab came from 4 trials: 2 on dupilumab monotherapy (SOLO‑1 and SOLO‑2) and 2 on dupilumab plus topical corticosteroids as needed (CAFÉ and CHRONOS). All patients had best ...
3.4 The marketing authorisation for dupilumab is for 'moderate to severe atopic dermatitis in adults who are candidates for systemic therapy'. The company only submitted evidence for dupilumab as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results